Eribulin and capecitabine, a combined treatment schedule in elderly metastatic breast cancer (EMBC)

Trial Profile

Eribulin and capecitabine, a combined treatment schedule in elderly metastatic breast cancer (EMBC)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Sep 2015

At a glance

  • Drugs Capecitabine (Primary) ; Eribulin (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Sep 2015 New trial record
    • 03 Jun 2014 Interim results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top